Lamivudin a dolutegravir
Economic Operator with Whom the Contract Has Been Concluded
| Show detail | ||||||||
|---|---|---|---|---|---|---|---|---|
| 1433/2022-SML | 07. 09. 2022 | GlaxoSmithKline, s.r.o. | 492 870 840,00 | 44 806 440,00 | 492 870 840,00 | 44 806 440,00 | CZK |
Published Documents
| Show detail | |||||
|---|---|---|---|---|---|
| Písemná zpráva zadavatele_Lamivudin a dolutegravir_EP.pdf | Písemná zpráva zadavatele | 13. 09. 2022 06:27 | Dokument není zavirovaný |
List of Participants
| Show detail | ||||||
|---|---|---|---|---|---|---|
| GlaxoSmithKline, s.r.o. | Praha | 492 870 840,00 | 44 806 440,00 | CZK |
Price Actually Paid in Each Year of Performance
| 1433/2022-SML | 2023 | 16 593 318,05 | 15 084 834,69 |
| 1433/2022-SML | 2022 | 3 450 096,00 | 3 136 450,91 |